A Agilent Technologies Inc.

Agilent Announces New ProteoAnalyzer System

(NYSE: A) today announced the release of a new automated parallel capillary electrophoresis system for protein analysis – the – at the , being held January 16-19 in San Diego. This new platform simplifies and improves the efficiency of analyzing complex protein mixtures, a process central to analytical workflows across the pharma, biotech, food analysis, and academia sectors.

Capillary electrophoresis (CE) has established itself as an indispensable tool for protein separation, as it offers rapid, high-resolution analysis with minimal sample consumption. The expanding interest of biopharma in monoclonal antibodies and other protein targets of potential therapeutic interest is driving the expected growth in demand for CE solutions.

The Agilent ProteoAnalyzer system brings added efficiency, versatility, and reliability, particularly in protein QC workflows. Automating the separation, data processing, and simplifying sample preparation steps streamlines the analysis workflow, which improves efficiency and reduces training and related labor costs. The system also can analyze a wide range of sample types, from crude lysates to purified fractions. It can analyze different sizes and types of proteins in a single run and consistently deliver accurate results, reducing the need for time-consuming and costly reanalysis.

“The Agilent ProteoAnalyzer system introduces a new level of efficiency, versatility, and reliability to protein analysis,” commented Knut Wintergerst, vice president and general manager of the Biomolecular Analysis Division at Agilent. “Automated parallel capillary electrophoresis simplifies the analysis of complex mixtures, benefiting diverse sectors from pharma to academia. Precision and reliability converge, reducing labor costs and enhancing analytical workflows.”

Kyle Luttgeharm, product manager in Agilent’s Integrated Genomics Division will present a seminar at PepTalk on Thursday, January 18 at 12:25 p.m., titled Discover the ProteoAnalyzer System: Automated Protein Analysis Parallel to None.

Agilent, one of the market leaders in CE, offers automated electrophoresis systems that see wide use for nucleic acids analysis, such as NGS QC and IVT RNA applications. Agilent expects the ProteoAnalyzer to strengthen its position as a key provider of quality control analysis solutions by extending its CE portfolio across relevant biomolecule classes.

About Agilent Technologies

(NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
16/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch